CombiGene’s research on the antiepileptic properties of neuropeptide Y and the Y2 receptor attracts international attention. Today, August 29th, 2018, the PhD student Esbjörn Melin will present the results of the preclinical long-term study conducted by CombiGene together with Professor Mérab Kokaia and his team at the Epilepsy Center in Lund. The oral presentation will take place at the 13th European Congress on Epileptology in Vienna, Austria.
The team at CombiGene wishes Esbjörn all the best with his presentation at this important congress!